NO20042124L - Thymosinforsterkning ved genetisk immunisering - Google Patents

Thymosinforsterkning ved genetisk immunisering

Info

Publication number
NO20042124L
NO20042124L NO20042124A NO20042124A NO20042124L NO 20042124 L NO20042124 L NO 20042124L NO 20042124 A NO20042124 A NO 20042124A NO 20042124 A NO20042124 A NO 20042124A NO 20042124 L NO20042124 L NO 20042124L
Authority
NO
Norway
Prior art keywords
hepatitis
virus
thymosin
enhancement
genetic immunization
Prior art date
Application number
NO20042124A
Other languages
English (en)
Norwegian (no)
Inventor
Jack R Wands
Original Assignee
Rhode Island Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhode Island Hospital filed Critical Rhode Island Hospital
Publication of NO20042124L publication Critical patent/NO20042124L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/2292Thymosin; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/29Hepatitis virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55516Proteins; Peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24211Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24211Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
NO20042124A 2001-10-26 2004-05-24 Thymosinforsterkning ved genetisk immunisering NO20042124L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33063801P 2001-10-26 2001-10-26
PCT/US2002/034535 WO2003035010A2 (en) 2001-10-26 2002-10-28 Thymosin augmentation of genetic immunization

Publications (1)

Publication Number Publication Date
NO20042124L true NO20042124L (no) 2004-05-24

Family

ID=23290629

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20042124A NO20042124L (no) 2001-10-26 2004-05-24 Thymosinforsterkning ved genetisk immunisering

Country Status (21)

Country Link
US (1) US20050054845A1 (es)
EP (1) EP1448223B1 (es)
JP (1) JP2005506997A (es)
KR (1) KR100902197B1 (es)
CN (1) CN1269524C (es)
AT (1) ATE382365T1 (es)
BR (1) BR0213554A (es)
CA (1) CA2464795A1 (es)
CY (1) CY1107371T1 (es)
DE (1) DE60224435T2 (es)
DK (1) DK1448223T3 (es)
EA (1) EA006743B1 (es)
ES (1) ES2299626T3 (es)
IL (1) IL161603A0 (es)
MX (1) MXPA04003867A (es)
NO (1) NO20042124L (es)
NZ (1) NZ532863A (es)
PL (1) PL370453A1 (es)
PT (1) PT1448223E (es)
UA (1) UA81613C2 (es)
WO (1) WO2003035010A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ555571A (en) * 2004-12-06 2009-02-28 Sciclone Pharmaceuticals Inc Alpha thymosin peptides as cancer vaccine adjuvants
CN102458470B (zh) * 2009-05-08 2016-01-20 赛生制药有限公司 作为疫苗增强剂的α胸腺素肽

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4079127A (en) * 1976-10-28 1978-03-14 Board Of Regents Of The University Of Texas Thymosin alpha 1
US4116951A (en) * 1977-04-22 1978-09-26 Hoffmann-La Roche Inc. [Asn2 ]-thymosin α1 and analogs thereof
US4148788A (en) * 1978-01-23 1979-04-10 Hoffmann-La Roche Inc. Synthesis of thymosin α1
DE2919592A1 (de) * 1979-05-15 1981-01-15 Max Planck Gesellschaft Verfahren zur herstellung von thymosin- alpha 1 und derivaten davon
TW224053B (es) * 1991-09-13 1994-05-21 Paul B Chretien
US5620896A (en) * 1992-03-23 1997-04-15 University Of Massachusetts Medical Center DNA vaccines against rotavirus infections
US5593972A (en) * 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US6288033B1 (en) * 1998-09-25 2001-09-11 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis B infection with thymosin alpha 1 in combination with lamivudine or in combination with lamivudine and famciclovir

Also Published As

Publication number Publication date
KR100902197B1 (ko) 2009-06-11
PL370453A1 (en) 2005-05-30
DE60224435D1 (de) 2008-02-14
ATE382365T1 (de) 2008-01-15
PT1448223E (pt) 2008-01-23
CA2464795A1 (en) 2003-05-01
IL161603A0 (en) 2004-09-27
EA006743B1 (ru) 2006-04-28
US20050054845A1 (en) 2005-03-10
EA200400534A1 (ru) 2004-12-30
KR20040089075A (ko) 2004-10-20
DK1448223T3 (da) 2008-02-18
JP2005506997A (ja) 2005-03-10
WO2003035010A2 (en) 2003-05-01
MXPA04003867A (es) 2005-06-17
EP1448223A4 (en) 2005-11-16
EP1448223A2 (en) 2004-08-25
ES2299626T3 (es) 2008-06-01
WO2003035010A3 (en) 2003-12-04
UA81613C2 (ru) 2008-01-25
CY1107371T1 (el) 2012-12-19
DE60224435T2 (de) 2009-01-02
EP1448223B1 (en) 2008-01-02
NZ532863A (en) 2006-07-28
CN1269524C (zh) 2006-08-16
CN1604789A (zh) 2005-04-06
BR0213554A (pt) 2004-10-26

Similar Documents

Publication Publication Date Title
WO2006041866A3 (en) Prevention and treatment of hcv infection employing antibodies directed against conformational and linear epitopes
EP1200109A4 (en) USE OF PEPTIDE NUCLEIC ACID COMPOUNDS TO TRIGGER CELLULAR IMMUNE RESPONSES TO HEPATITIS C
WO2006086188A3 (en) Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants
WO2001058485A3 (en) Prophylactic and therapeutic antibodies against vaccina virus antigens
TW200641126A (en) N protein mutants of porcine reproductive and respiratory syndrome virus
MXPA06013388A (es) Vector lentiviral recombinante para la expresion de una proteina flaviviridae y sus aplicaciones como vacuna.
MXPA05005203A (es) Vacuna contra vhc.
WO2005028496A3 (en) Vaccine for treatment and prevention of herpes simplex virus infection
DK1949913T3 (da) Immunstimulatorisk kombination til profylakserne og behandlingen af hepatitis C
BR0108499A (pt) Agente terapêutico para hepatite c
DK1471936T3 (da) HIV-Vaccine og fremgangsmåde til anvendelse
WO2001096370A3 (en) Cryptosporidium parvum antigens, antibodies thereto and diagnostic and therapeutic compositions thereof
WO2007121491A8 (en) Hcv vaccinations
WO2002057314A3 (en) Prevention and treatment of hcv infection employing antibodies directed against conformational epitopes
WO2004005316A3 (en) Prevention and treatment of hcv infection employing antibodies directed against conformational and linear epitopes
MX2022002270A (es) Vacunas contra el virus de la hepatitis b.
NO20042124L (no) Thymosinforsterkning ved genetisk immunisering
EA200301151A1 (ru) Вакцина против натуральной оспы
WO2003093298A3 (en) Immunogenic peptides
WO2004058807A3 (en) Mhc class i restricted t-cell stimulating peptides from hepatitis b virus
WO2005056051A3 (en) Hepatitis b vaccines and compositions
DK1301637T3 (da) DNA-vacciner, der koder for HIV accessoriske proteiner
WO2002026785A3 (de) Cd4+ t-lymphozyten spezifische hepatitis c virus-epitope
ATE476197T1 (de) Rekombinante vakzine gegen infektion mit dem japanischen enzephalitis-virus äjevü und verfahren davon
DE10393824D2 (de) Impfstoff gegen Infektionen mit Onkoviren, wie dem felinen Leukosevirus der Katze

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application